WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998000434) MODIFIED OLIGONUCLEOTIDES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/000434    International Application No.:    PCT/EP1997/003192
Publication Date: 08.01.1998 International Filing Date: 19.06.1997
Chapter 2 Demand Filed:    11.12.1997    
IPC:
C07H 21/00 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH) (For All Designated States Except US).
DE MESMAEKER, Alain [BE/CH]; (CH) (For US Only).
WENDEBORN, Sebastian [DE/CH]; (CH) (For US Only).
LEBRETON, Jacques [FR/FR]; (FR) (For US Only)
Inventors: DE MESMAEKER, Alain; (CH).
WENDEBORN, Sebastian; (CH).
LEBRETON, Jacques; (FR)
Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH)
Priority Data:
96810431.5 28.06.1996 EP
Title (EN) MODIFIED OLIGONUCLEOTIDES
(FR) OLIGONUCLEOTIDES MODIFIES
Abstract: front page image
(EN)It is one object of the present invention to provide an oligonucleotide of formula (1): 5'-(U)¿n?-3' in which U is an identical or different radical of a natural or a synthetic nucleoside, wherein the oligonucleotide comprises at least one modified nucleotide dimer comprising two nucleoside analogs connected via an amide-bond that has a certain configuration; the synthesis of these compounds and their use in pharmaceutical preparations.
(FR)L'invention porte notamment sur un oligonucléotide défini par la formule (1) 5'-(U)¿n?-3', dans laquelle U représente des radicaux, identiques ou différents, d'un nucléoside naturel ou synthétique. Cet oligonucléotide comporte au moins un nucléotide dimère modifié composé de deux analogues de nucléosides reliés par une liaison amide présentant une configuration particulière. L'invention concerne également la synthèse de ces composés et leur utilisation dans des préparations pharmaceutiques.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)